drugset / Trial / NCT02866175

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

NCT02866175

RandomizedParallel-groupOpen-labelTreatment

Summary

There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation (AF) following percutaneous intervention (PCI) with stenting. This study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a vitamin K antagonist (VKA)-based antithrombotic regimen in subjects with AF following PCI with stent placement. Bleeding is a central safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies and invasive procedures.

Timeline

Start
2017-02-24
Primary completion
2019-06-06
Completion
2019-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule 30 mg
Subject Edoxaban Small molecule 60 mg
Background Clopidogrel Small molecule 75 mg
Background Prasugrel Small molecule 5 mg
Background Prasugrel Small molecule 10 mg
Background Ticagrelor Small molecule 90 mg

Indications